Cancer's Favorite Weapon Is Getting a New Job in Autoimmune Disease

Those are cancer numbers, not autoimmune numbers. But they demonstrate the drug can wipe out B cells with serious efficiency.

The Money and the Mastermind

The entire $50 million Series A came from a single source: RTW Investments, the New York-based firm that has turned biotech company creation into an art form. RTW didn't just write the check; they founded Prolium.

This is RTW's signature move. The firm has a pattern of incubating startups from scratch, seeding them with licensed assets, and then scaling aggressively. Prolium joins a growing roster of RTW-created companies in the autoimmune space, including Yarrow Bioscience (targeting Graves' disease and thyroid eye disease) and Jade Biosciences (going after IgA nephropathy, a chronic autoimmune kidney condition). About 17% of RTW's portfolio is allocated to inflammation and immunology.

The underlying technology comes from a partnership between two China-based companies, KeyMed Biosciences and InnoCare Pharma. Prolium holds exclusive global rights to develop PRO-203 in non-oncology indications, plus rights outside Asia for oncology. KeyMed and InnoCare stand to receive up to $520 million in milestone payments plus royalties, and they maintain a minority equity stake in Prolium. That's a hefty licensing deal, signaling real confidence that autoimmune applications can generate oncology-scale revenue.

Where Things Stand in the Clinic

Prolium isn't starting from zero. A single ascending dose study in healthy volunteers is already underway, testing basic safety and how the drug behaves in the body. A multinational Phase 1/2 trial in systemic sclerosis patients is expected to launch in Q2 2026, meaning enrollment could begin as soon as April.

There's also an intriguing signal from an investigator-initiated study: five patients with treatment-refractory lupus (including lupus nephritis) have already been dosed. Results are pending presentation at a future medical conference. If those early lupus data look promising, it could broaden the story significantly.

Beyond systemic sclerosis, Prolium plans to start additional trials this year in other B-cell driven autoimmune conditions, though the company hasn't specified which ones yet.

A Crowded (and Exciting) Race

Prolium isn't the only team running this play. The idea of repurposing oncology's bispecific antibodies for autoimmune disease is catching fire across the industry.

Roche/Genentech reported 2025 data on mosunetuzumab in granulomatosis with polyangiitis, a form of vasculitis. And then there's EvolveImmune, which is taking things a step further with EVOLVE205, a trispecific antibody (imagine three arms instead of two) that showed superior potency against low-CD20 B cells in preclinical work presented at AACR 2025.

The field is also watching CAR-T therapy closely. Programs like C-CAR168, a bispecific CAR-T targeting both CD20 and BCMA, posted a 77.8% renal response rate in refractory lupus nephritis patients. But CAR-T requires manufacturing a custom product from each patient's own cells, making it expensive and logistically brutal. T-cell engagers are off-the-shelf drugs: a vial in a fridge, ready to infuse. That scalability advantage is enormous if the efficacy holds up.

The Elephant in the Room: Safety

There's a reason T-cell engagers weren't tried in autoimmune patients first. These drugs activate T cells, and activated T cells release a flood of inflammatory signals called cytokines. In cancer treatment, this can cause cytokine release syndrome (CRS), a potentially life-threatening reaction that ranges from mild flu-like symptoms to organ failure.

Oncology teams manage CRS with step-up dosing (starting low and gradually increasing) and it's typically limited to early treatment cycles. But cancer patients are often willing to accept serious side effects because the alternative is worse. Autoimmune patients are a different calculus entirely. A 35-year-old with systemic sclerosis needs a treatment that won't put them in the ICU.

How Prolium manages this risk will define whether PRO-203 becomes a real therapy or a cautionary tale. The healthy volunteer study currently underway should provide early safety signals, and the Phase 1/2 design will presumably incorporate careful dose escalation.

The Bottom Line

Prolium's emergence is a milestone for a trend that's been building quietly: oncology's most powerful tools are being redirected at autoimmune disease. The science makes sense. B cells drive many severe autoimmune conditions, and T-cell engagers kill B cells better than anything else we've seen. The business case makes sense too, with a massive patient population poorly served by current therapies.

But the gap between "makes sense" and "works in patients" is where most drugs go to die. Prolium has money, a drug that's already dosing, and a well-connected backer in RTW. Now comes the hard part: proving that a weapon designed for cancer can be gentle enough for everything else.

The Eczema Drug That Got Killed by a Cancer Signal

Kyowa Kirin just killed its most promising eczema drug after cancer cases emerged in clinical trials. The culprit? A mechanism that was supposed to be its biggest advantage may have been disabling the body's cancer defenses all along.